ZYBERNO
Stock Report
Updated Sep 1, 2026

TSCAN THERAPEUTICS, INC. (TCRX)

Healthcare • NASDAQ

$0.73

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
13.0/100
POOR BUSINESS
TSCAN THERAPEUTICS, INC. (TCRX) scores 13/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-108.7%)
Debt-to-Equity (Solvency Risk):POOR (1.20x)
Operating Margin (Operational Efficiency):CRITICAL (-1,695.1%)
Return on Capital (Capital Efficiency):CRITICAL (-5,505.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

TSCAN THERAPEUTICS, INC. (TCRX) stock report — Zyberno Score 13/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TCRX generated -$123.72M in Owner Earnings. Capital was deployed as follows: $2.95M invested in capital expenditures. Reinvestment rate: -1.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.73
Market Cap:$94.82M

Valuation Multiples (3)

P/B Ratio:1.37x
P/S Ratio:13.33x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$27.45M

Price Action & Momentum (3)

Momentum Percentile:15 / 100
% of 52-Week High:28.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-54.5%
Reinvestment Rate:-1.7%
Fundamental Growth Rate (g):91.8%

Margin Analysis (3)

Operating Margin Ttm:-1,695.1%
Net Margin Ttm:-1,655.4%
Ebitda Margin:-1,654.6%

TTM Performance (2)

Operating Margin Ttm:-1,695.1%
Net Margin Ttm:-1,655.4%

Yield Metrics (2)

Earnings Yield:-$117.88
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-159.6%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-26.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.37x
Quick Ratio:3.37x
Cash Ratio:3.23x

Leverage Analysis (3)

Debt To Equity Ttm:1.20x
Debt-to-Equity Ratio:1.20x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-48.70x
Times Interest Earned:-48.70

Capital Structure (4)

Working Capital:73,439,000.00
Cash And Cash Equivalents:100,156,000.00
Long Term Debt:$21.07M
Net Debt:-$67.38M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $7.11M
Linear Growth: -26.2%
📊 Click to view full TCRX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$120.54M

Bottom Line Performance (3)

-$117.71M
Income Before Tax:$0.00
Ebitda Ttm:-117,661,000.00

Operating Expenses (5)

Operating Expenses:127,653,000.00
R And D Expense:97,034,000.00
Sga Expense:30,619,000.00
Income Tax Expense:$0.00
Interest Expense:2,789,000.00

Expense Ratios (3)

R And D To Revenue Percentage:9,232.5%
Sga To Revenue Percentage:2,913.3%
Ebitda Margin:-1,654.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$171.45M
Current Assets:$104.40M
Ppe Net:7,743,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:102,433,000.00
Current Liabilities:30,964,000.00
Long Term Debt:$21.07M
Short Term Debt:$11.71M

Equity & Capital (3)

Equity:$69.02M
Retained Earnings:-$563.89M
Common Stock:165,210,543.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,122,000.00

Special Items (2)

Contract Liabilities:586,000.00
Stock Based Compensation:2,465,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$122.01M-$124.96M

Investment Activities (2)

Investing Cash Flow:-$70.00K
Capital Expenditures Ttm:2,945,000.00

Financing Activities (3)

Financing Cash Flow:$73.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:33,131,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,881,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.91
-$0.91
Earnings Per Share Ttm:-$0.91

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$1.04

Book Value & Capital (2)

Book Value Per Share:$0.53
Cash Per Share:0.77

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.10x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:160.25
Cash Conversion Cycle:-2,158.25
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$123.72M

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.7%
Fundamental Growth Rate (g):91.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-26.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-2.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:TCRX
Company Name:TSCAN THERAPEUTICS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:129.95M
Shares Outstanding Basic:129.95M
Shares Outstanding Diluted:129.95M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 00:04:36 UTC
Data Timestamp:2026-08-20T04:40:36.866840
Scroll to Top